contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioporto-one-pager-capital-secured-via-private-placement

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Equity Research Analyst

Philip Coombes

BioPorto är verksamt inom bioteknik. Bolaget tillverkar och marknadsför tester för diagnostisering av diverse allvarliga sjukdomar. Produktportföljen består av egenutvecklade antikroppsläkemedel som används för farmaceutisk bruk samt inom diverse forskningssammanhang. Produkterna återfinns på global nivå och används exempelvis vid behandling och analys av fetma, diabetes och diverse allergier.

BioPorto

Bioporto (One-pager): Capital secured via private placement

<div class="page" title="Page 1">
<div class="section">
<div class="layoutArea">
<div class="column">
<p><strong>Investment case:</strong></p>
<p>BioPorto is scaling the sales of its FDA-approved ProNephro AKI (NGAL) pediatric test and NGAL test for RUO, particularly in the US. The company looks to convert rising awareness to sustainable recurring revenues in the AKI diagnostic market, estimated to have a total addressable market (TAM) of USD 3.0 billion[1] and a 5% CAGR, supported by a shift in diagnostic paradigms.</p>
<p>In 2024, NGAL sales grew 34% y/y in the US and 24% y/y total as BioPorto progresses towards its ambitions for revenue of DKK 80- 125m in 2026 (cash flow positive by end-2026) and DKK +700m (USD +100m) by 2029. Increased sales activities will be supported by existing partnerships with Roche and Beckman Coulter, two of BioPorto&#x2019;s five key prioritized partners, and additional partnerships. The NGAL test is FDA-approved for Roche platforms, with Beckman Coulter FDA-approval expected in 2026.</p>
<p>BioPorto may also benefit from inclusion in the KDIGO (Kidney Disease: Improving Global Outcomes) best-practice guidelines, which are expected to be updated in late 2025 and take effect in H1 2026. KDIGO inclusion can drive pull-through demand in the market as reimbursement decisions in developed healthcare systems often align with KDIGO recommendations. Inclusion would position the NGAL test to be the preferred diagnostic tool.</p>
<p>Using a DCF model (see pages 2 and 3), we find that the market implies a Probability of Success (PoS) exceeding 100% for the pediatric ProNephro AKI (NGAL) launch, indicating full pricing of its successful commercialization in the U.S. However, when also considering NGAL for adult use, broader applications, and global markets&#x2014;representing a TAM of USD 3 billion annually&#x2014;the market implied base case PoS is around 43%.</p>
<p>Disclaimer: <span lang="EN-US">HC Andersen Capital receives payment from Bioporto for a Digital IR/Corporate Visibility subscription agreement. /</span><span lang="EN-US">Claus Thestrup</span><span lang="EN-US"> 4:35 PM, 15-04-2025, updated 17:00 24-04-2025</span></p>
</div>
</div>
</div>
</div>